GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration

BACKGROUND: CD133(+) stem cells represent a promising subpopulation for innovative cell-based therapies in cardiovascular regeneration. Several clinical trials have shown remarkable beneficial effects following their intramyocardial transplantation. Yet, the purification of CD133(+) stem cells is ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Skorska, Anna, Müller, Paula, Gaebel, Ralf, Große, Jana, Lemcke, Heiko, Lux, Cornelia A., Bastian, Manuela, Hausburg, Frauke, Zarniko, Nicole, Bubritzki, Sandra, Ruch, Ulrike, Tiedemann, Gudrun, David, Robert, Steinhoff, Gustav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303262/
https://www.ncbi.nlm.nih.gov/pubmed/28187777
http://dx.doi.org/10.1186/s13287-016-0467-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303262/
https://www.ncbi.nlm.nih.gov/pubmed/28187777
http://dx.doi.org/10.1186/s13287-016-0467-0

Ejemplares similares